A Phase I, Multicenter, Open-Label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients With Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Abivertinib-maleate (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors ACEA Biosciences
- 17 Feb 2018 Planned number of patients changed from 100 to 60.
- 17 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Sep 2019.
- 17 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2019.